Xenon Pharmaceuticals Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing balance sheet data showing total assets of $1,199,875 thousand and an accumulated deficit of $1,568,853 thousand.

Key Highlights

  • Total assets of $1,199,875 thousand as of September 30, 2026, up from $633,163 thousand at December 31, 2025, according to the filing.
  • Marketable securities totaled $1,070,918 thousand combined across current ($868,238 thousand) and non-current ($202,680 thousand) categories as of September 30, 2026.
  • Cash and cash equivalents declined to $82,560 thousand at September 30, 2026, from $199,163 thousand at December 31, 2025.
  • Accumulated deficit reached $1,568,853 thousand at September 30, 2026, compared with $1,245,380 thousand at December 31, 2025.
  • Common shares outstanding were 98,275,278 as of September 30, 2026, up from 80,010,790 at December 31, 2025.
  • Total shareholders' equity stood at $1,146,382 thousand at September 30, 2026, versus $581,760 thousand at December 31, 2025.

Xenon Pharmaceuticals Balance Sheet Expansion in Third Quarter 2026

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a Canada-incorporated biopharmaceutical company headquartered in Burnaby, British Columbia, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing reported total assets of $1,199,875 thousand, a substantial increase from $633,163 thousand recorded at December 31, 2025. The company disclosed that the common shares outstanding rose to 98,275,278 from 80,010,790 over the same period, with the company reporting 98,284,734 common shares outstanding as of November 5, 2026.

According to the filing, common shares capital increased to $2,492,998 thousand at September 30, 2026, from $1,598,571 thousand at December 31, 2025, reflecting the growth in shares issued during the period. Total shareholders' equity nearly doubled to $1,146,382 thousand from $581,760 thousand. The accumulated deficit widened by approximately $323,473 thousand over the nine-month period, reaching $1,568,853 thousand. The company also reported accumulated other comprehensive loss of $5,053 thousand at September 30, 2026, compared with accumulated other comprehensive income of $335 thousand at December 31, 2025.

The filing stated that total current liabilities were $45,304 thousand and total liabilities were $53,493 thousand at September 30, 2026. The company disclosed that its business "substantially depends upon the successful development of azetukalner," and noted that it "has incurred significant losses since our inception and anticipates that we will continue to incur significant losses for the foreseeable future." The registrant is classified as a large accelerated filer and is listed on the Nasdaq Global Market.

What Was Disclosed

Xenon Pharmaceuticals filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, share counts, marketable securities positions, and a summary of principal business risks including dependence on azetukalner development.